The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma

医学 浆液性液体 靶向治疗 肿瘤科 生物标志物 背景(考古学) 恶性肿瘤 内科学 浆液性癌 癌症研究 癌症 卵巢癌 生物 生物化学 古生物学
作者
Karen L. Talia,Natalie Banet,Natália Buza
出处
期刊:Pathology [Elsevier BV]
卷期号:55 (1): 8-18 被引量:16
标识
DOI:10.1016/j.pathol.2022.11.004
摘要

Human epidermal growth factor receptor 2 (HER2) is a prognostic biomarker and therapeutic target in carcinomas of the breast, stomach and colon. In 2018, clinical trial data confirmed the prognostic and predictive role of HER2 in uterine serous carcinoma, with a demonstrated survival benefit from combined chemotherapy and anti-HER2 targeted therapy in patients with advanced or recurrent disease. Approximately one-third of uterine serous carcinomas demonstrate HER2 protein overexpression and/or gene amplification and HER2 immunohistochemistry, supplemented by in situ hybridisation in equivocal cases, is fast becoming a reflex ancillary test at time of diagnosis. The potential role of HER2 in gynaecological tumours other than uterine serous carcinoma is yet to be firmly established. With the advent of personalised medicine, routine tumour sequencing and pursuit of targeted therapies, this is a field currently under active investigation. Emerging data suggest triaging endometrial carcinomas for HER2 analysis based on molecular classification may be superior to histotype-based testing, with copy-number high/p53 mutant tumours enriched for HER2 overexpression or amplification. Accordingly, many carcinosarcomas and a subset of clear cell and high-grade endometrioid carcinomas may be eligible for HER2 targeted therapy, although any clinical benefit in this context is currently undefined. For ovarian carcinomas, combined data support the role of HER2 as a prognostic biomarker, however its use as a therapeutic target is yet to be elucidated through clinical trials. In the cervix, reported rates of HER2 overexpression vary and are generally low, and currently there is insufficient evidence to justify routine HER2 testing in this context. Limited data suggest HER2 holds promise as a prognostic and predictive biomarker in vulvar Paget disease. Future clinical trials, with pathologist input to develop and refine site-specific scoring criteria, are required to establish what role HER2 might play more broadly in gynaecological cancer care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小董不懂完成签到,获得积分10
1秒前
椰子完成签到,获得积分10
1秒前
沐沐溪三清完成签到,获得积分10
1秒前
2秒前
刘丰完成签到 ,获得积分10
4秒前
郑桂庆完成签到 ,获得积分10
5秒前
zhang完成签到 ,获得积分10
5秒前
yuchen完成签到,获得积分10
6秒前
喜悦的水云完成签到 ,获得积分10
6秒前
7秒前
zhaokunfeng完成签到,获得积分10
7秒前
Y123发布了新的文献求助10
7秒前
wu完成签到,获得积分10
7秒前
高高诗柳完成签到 ,获得积分10
7秒前
王金豪完成签到,获得积分10
7秒前
LSS完成签到,获得积分10
7秒前
榜一大哥的负担完成签到 ,获得积分10
8秒前
Lucas应助qi0625采纳,获得10
8秒前
顾矜应助以筱采纳,获得10
9秒前
景清完成签到,获得积分10
9秒前
细心香烟完成签到 ,获得积分10
9秒前
hu完成签到 ,获得积分10
9秒前
HQ完成签到,获得积分10
9秒前
10秒前
水清木华完成签到,获得积分10
10秒前
11秒前
miao完成签到,获得积分20
11秒前
xyp_zjut应助学术乞丐采纳,获得10
11秒前
Lucas应助凉白开采纳,获得10
11秒前
体贴凌柏发布了新的文献求助10
12秒前
12秒前
12秒前
鹿子完成签到 ,获得积分10
12秒前
秋枫忆完成签到,获得积分10
14秒前
宋立发布了新的文献求助10
14秒前
孤独的AD钙完成签到,获得积分10
14秒前
15秒前
fang应助miao采纳,获得10
16秒前
星辰与月完成签到,获得积分10
16秒前
Pt-SACs发布了新的文献求助10
16秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029